LU45106A1 - - Google Patents

Info

Publication number
LU45106A1
LU45106A1 LU45106DA LU45106A1 LU 45106 A1 LU45106 A1 LU 45106A1 LU 45106D A LU45106D A LU 45106DA LU 45106 A1 LU45106 A1 LU 45106A1
Authority
LU
Luxembourg
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU45106A1 publication Critical patent/LU45106A1/xx

Links

LU45106D 1962-12-27 1963-12-23 LU45106A1 (pm)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP5790262 1962-12-27
JP6427663 1963-10-29
JP5741963 1963-10-29
JP6250163 1963-11-22

Publications (1)

Publication Number Publication Date
LU45106A1 true LU45106A1 (pm) 1964-02-24

Family

ID=27463499

Family Applications (1)

Application Number Title Priority Date Filing Date
LU45106D LU45106A1 (pm) 1962-12-27 1963-12-23

Country Status (5)

Country Link
BE (1) BE641880A (pm)
FR (1) FR3150M (pm)
GB (1) GB1080599A (pm)
LU (1) LU45106A1 (pm)
NL (1) NL302572A (pm)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2495608A1 (fr) * 1980-12-04 1982-06-11 Morelle Jean Nouveaux derives de l'acide aspartique et leurs usages
EP1824563B1 (en) 2004-11-26 2010-02-10 UCL Business PLC Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
CA3205755A1 (en) 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
AU2011312042B2 (en) 2010-10-06 2015-08-20 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
EP3223829B1 (en) 2014-11-24 2019-10-23 UCL Business Plc. Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
KR20200024145A (ko) 2017-05-11 2020-03-06 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제조방법
CN107540413A (zh) * 2017-09-14 2018-01-05 精晶药业股份有限公司 一种从门冬氨酸鸟氨酸结晶母液中提取尿素的方法

Also Published As

Publication number Publication date
NL302572A (pm)
FR3150M (fr) 1965-02-22
BE641880A (pm) 1964-04-16
GB1080599A (en) 1967-08-23

Similar Documents

Publication Publication Date Title
BE628579A (pm)
BE626723A (pm)
AU269855A (pm)
LU45106A1 (pm)
BE615244A (pm)
BE616920A (pm)
BE634821A (pm)
BE633765A (pm)
BE633687A (pm)
BE633210A (pm)
BE632887A (pm)
BE632633A (pm)
BE631376A (pm)
BE629169A (pm)
BE628347A (pm)
BE627004A (pm)
BE626971A (pm)
BE621553A (pm)
BE620644A (pm)
BE620399A (pm)
CH866363A4 (pm)
BE629953A (pm)
BE629926A (pm)
BE628792A (pm)
BE629893A (pm)